IGM BIOSCIENCES INC (IGMS) Stock News
NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD
IGMS Latest News, Press Relases and Analysis
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences (IGMS) delivered earnings and revenue surprises of -109.76% and 91.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MRSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -6.52% and 122.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: OBIO
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 337.50% and 235.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: GLUE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ: IGMS). Such investors...
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover
The company is making a complete shift out of oncology and into autoimmune diseases.
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and...
IGMS Stock Earnings: IGM Biosciences Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IGM Biosciences (NASDAQ:IGMS) just reported results for the second quarter of 2...
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – ...
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis...
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
IGMS Stock Earnings: IGM Biosciences Misses EPS, Misses Revenue for Q2 2024
IGMS stock results show that IGM Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose...